Imaging matrix metalloproteinases in cancer

被引：148

作者：

Scherer, Randy L. ^{[1
,2
]}

McIntyre, J. Oliver ^{[1
,3
]}

Matrisian, Lynn M. ^{[1
,3
]}

机构：

[1] Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37232 USA

[2] Vanderbilt Univ, Interdisciplinary Program Mat Sci, Nashville, TN 37235 USA

[3] Vanderbilt Univ, Inst Imaging Sci, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA

来源：

CANCER AND METASTASIS REVIEWS | 2008年 / 27卷 / 04期

基金：

美国国家科学基金会;

关键词：

near infrared; MMP; in vivo imaging; MRI; PET; SPECT;

D O I：

10.1007/s10555-008-9152-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Early detection of both primary tumors and metastatic disease remains a major challenge in the diagnosis and staging of cancer. The recognition of the role of MMPs in both the growth and metastasis of tumors has guided the development not only of therapeutic strategies utilizing synthetic, small-molecule MMP inhibitors (MMPIs), but has also catalyzed methods to detect and image tumors in vivo by means of tumor-associated proteolytic activity. These imaging approaches target MMPs involved in cancer progression via contrast agents linked to MMPIs or to MMP selective and specific substrates with sensitivity enhanced by amplification during enzymatic processing. This review draws attention to a variety of strategies utilized to image MMP activity in vivo.

引用

页码：679 / 690

页数：12

共 58 条

[1] Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth doxorubicin with less toxicity [J].

Albright, CF ;

Graciani, N ;

Han, W ;

Yue, E ;

Stein, R ;

Lai, ZH ;

Diamond, M ;

Dowling, R ;

Grimminger, L ;

Zhang, SY ;

Behrens, D ;

Musselman, A ;

Bruckner, R ;

Zhang, MZ ;

Jiang, X ;

Hu, D ;

Higley, A ;

DiMeo, S ;

Rafalski, M ;

Mandlekar, S ;

Car, B ;

Yeleswaram, S ;

Stern, A ;

Copeland, RA ;

Combs, A ;

Seitz, SP ;

Trainor, GL ;

Taub, R ;

Huang, P ;

Oliff, A .

MOLECULAR CANCER THERAPEUTICS, 2005, 4 (05) :751-760

[2] In vivo molecular target assessment of matrix metalloproteinase inhibition [J].

Bremer, C ;

Tung, CH ;

Weissleder, R .

NATURE MEDICINE, 2001, 7 (06) :743-748

[3] Clinical studies with matrix metalloproteinase inhibitors [J].

Brown, PD .

APMIS, 1999, 107 (01) :174-180

[4] Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging [J].

Choyke, PL ;

Dwyer, AJ ;

Knopp, MV .

JOURNAL OF MAGNETIC RESONANCE IMAGING, 2003, 17 (05) :509-520

[5]

COSGROVE D, 2006, EUROPEAN J RADIOLOGY, V3, P324

[6]

DAVIES B, 1993, CANCER RES, V53, P5365

[7] Synthesis of radiolabeled biphenylsulfonamide matrix metalloproteinase inhibitors as new potential PET cancer imaging agents [J].

Fei, XS ;

Zheng, QH ;

Liu, XA ;

Wang, JQ ;

Sun, HB ;

Mock, BH ;

Stone, KL ;

Miller, KD ;

Sledge, GW ;

Hutchins, GD .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (13) :2217-2222

[8]

FRITZHANSEN T, 1996, MAGNETIC RESONANCE M, V2, P225

[9] Synthesis and characterization of a doxorubicin-Gd(III) contrast agent conjugate: A new approach toward prodrug-procontrast complexes [J].

Frullano, Luca ;

Tejerina, Baudilio ;

Meade, Thomas J. .

INORGANIC CHEMISTRY, 2006, 45 (21) :8489-8491

[10]

FUNOVICS MA, 2003, MOL IMAGING, V4, P350

← 1 2 3 4 5 6 →